All News
Enthesitis Responses to Secukinumab in Spondylitis Patients
Schett and colleagues studies the secukinumab (an IL-17 inhibitor) response in patients from 3 clinical trials with enthesitis and ankylosing spondylitis (AS) and demonstrated consistent efficacy with improved enthesitis scores at both peripheral and axial sites.
Read ArticleRheumatic Patients Are at Risk for COVID Death
Patients with rheumatic diseases who developed COVID-19 were at increased likelihood of death, with risk factors similar to those seen in the general population but also because of factors specific to their underlying disease and its treatment, analysis of data from an international registry foun
Read ArticleLinks:
Links:
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Links:
Links:
French review of 41 TRAPS pts w/ amyloidosis AA. AA dx preceded TRAPS in 96% of cases, 47% needed renal replacement therapy and 14% died at 23 most F/U. 19 pts took biologics, 10 improved, 7 stabilized, 4 worsened. AA pts should be screened for TRAPS https://t.co/tONNSRCoOU
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Links:
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Links:
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr. John Cush RheumNow ( View Tweet)